Skip to content

Vericel VCEL Net Investment in Lease

Net Investment in Lease at other companies

LeMaitre Vascular logo
LeMaitre VascularLMAT
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$68.4M+30.1%
Gross profit$49.3M+35.8%
Operating income-$8.1M+37.0%
Net income-$6.3M+44.0%
EPS (diluted)-$0.12+47.8%

Balance sheet

See full
Cash & equivalents$109.3M+37.1%
Total debt$95.0M-4.6%
Total equity$356.2M+20.6%
Total assets$485.6M+14.4%

Cash flow

See full
Operating cash flow$16.4M+148%
CapEx$1.3M-91.2%
Free cash flow$15.1M+299%

Valuation

See full
Market cap$2.13B-26.8%

Profitability

See full
Gross margin74.8%+2.3pp
Operating margin5.4%+4.6pp
Net margin7.3%+6.1pp
FCF margin16.3%

Returns & leverage

See full
Return on equity6.6%+5.5pp
Debt / equity0.3×-0.1×
Current ratio5.2×+0.2×

Where this comes from

Reported directly by Vericel in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Vericel’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vericel's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vericel's net investment in lease?
Vericel (VCEL) reported net investment in lease of $63.41M in Q1 2026.
How has Vericel's net investment in lease changed year-over-year?
Vericel's net investment in lease decreased by 7.7% year-over-year, from $68.72M to $63.41M.
What is the long-term trend for Vericel's net investment in lease?
Over 5 years (2020 to 2025), Vericel's net investment in lease has grown at a 5.3% compound annual growth rate (CAGR), from $50.11M to $64.77M.